title: Cardiovascular profile of loratadine.
abstract: The extremely low reporting rate of cardiovascular adverse events for loratadine, the possible preferential use of loratadine in patients with pre-existing cardiovascular disorders, and the impressive lack of cardiovascular effects at extremely high concentrations in clinical and preclinical studies demonstrate the very safe cardiovascular profile of loratadine.
authors.affiliation: Schering-Plough Research Institute, Kenilworth, New Jersey 07033, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Hey
authors.forename: M
authors.initials: M
authors.lastname: Affrime
authors.forename: B
authors.initials: B
authors.lastname: Cobert
authors.forename: W
authors.initials: W
authors.lastname: Kreutner
authors.forename: F M
authors.initials: FM
authors.lastname: Cuss
mesh_terms: D000818:Animals; D002319:Cardiovascular System / Q000187:drug effects*; D027682:Cation Transport Proteins; D004268:DNA-Binding Proteins; D004347:Drug Interactions; D000072237:ERG1 Potassium Channel; D004562:Electrocardiography / Q000187:drug effects; D051638:Ether-A-Go-Go Potassium Channels; D006634:Histamine H1 Antagonists / Q000009:adverse effects*; D006801:Humans; D017336:Loratadine / Q000009:adverse effects*; D015221:Potassium Channels / Q000187:drug effects; D024642:Potassium Channels, Voltage-Gated; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG
chemical_list: D027682:Cation Transport Proteins; D004268:DNA-Binding Proteins; C072312:ERG protein, human; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; D006634:Histamine H1 Antagonists; C092509:KCNH6 protein, human; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG; D017336:Loratadine